NASDAQ$DYN
Dyne Therapeutics Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2022 and business highlights.
Dyne Therapeutics reported a net loss of $52.3 million for the second quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $291.8 million as of June 30, 2022, which is anticipated to fund operations into the second half of 2024. They are on track for mid-2022 for initiation of patient dosing in multiple ascending dose clinical trials for DYNE-251 in DMD and DYNE-101 in DM1.
- Initiated Phase 1/2 multiple ascending dose (MAD) clinical trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1).
- FDA lifted the clinical hold and cleared its Investigational New Drug (IND) application to initiate its Phase 1/2 MAD clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 51.
- New in vivo data from DYNE-101 were presented at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting that demonstrated robust knockdown of DMPK RNA in multiple muscles with low monthly dosing in an innovative hTfR1/DMSXL mouse model developed by Dyne and in non-human primates.
- Cash, cash equivalents and marketable securities were $291.8 million as of June 30, 2022, which is anticipated to fund operations into the second half of 2024.
Headline financials
Revenue & EPS history
Dyne Therapeutics · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
+1.8%
Avg return
Earnings day
-2.5%
Avg return
5 days after
+3.0%
Avg return
30 days after
59%
13 / 22 earnings
Positive
+21.3%
Q3 2024
Best reaction
-6.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q4 2025 | +3.6% | -4.9% | +15.9% | |
| Q3 2025 | -2.8% | -14.0% | -5.8% | |
| Q2 2025 | -1.3% | +7.9% | +47.7% | |
| Q1 2025 | +1.1% | +3.6% | +30.1% | |
| Q4 2024 | -4.5% | -13.8% | -17.0% | |
| Q3 2024 | +21.3% | +0.9% | -9.0% | |
| Q2 2024 | +0.5% | +5.7% | -22.0% | |
| Q1 2024 | +1.0% | -0.7% | +23.4% | |
| Q4 2023 | -3.4% | -9.2% | -4.5% | |
| Q3 2023 | +6.5% | +24.3% | +66.0% | |
| Q2 2023 | -1.8% | -15.6% | +0.1% | |
| Q1 2023 | -4.0% | -4.6% | -7.4% | |
| Q4 2022 | +10.1% | +8.3% | -15.5% | |
| Q3 2022 | +1.6% | -4.9% | +15.8% | |
| Q2 2022 | +4.3% | +1.1% | +1.0% | |
| Q1 2022 | +10.5% | -16.4% | -45.0% | |
| Q4 2021 | -1.7% | -2.9% | +16.5% | |
| Q3 2021 | +2.0% | +0.7% | -10.4% | |
| Q2 2021 | +3.3% | -4.1% | -9.6% | |
| Q1 2021 | +5.1% | +0.2% | +1.9% | |
| Q4 2020 | -6.5% | -6.2% | -4.4% | |
| Q3 2020 | -5.0% | -9.6% | -1.5% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro